What if you could diagnose multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and concussions with a 10-second scan of the retina? Now, a combination of cellular-level imaging and artificial intelligence (AI) presents that possibility. It tracks movements of the retina instead of pupil movement. Because the retinal tracking technology measures eye motion on a cellular scale, it can detect movements as small as 1/100 the size of a human hair, which is about 120 times more sensitive than other eye-tracking systems. The new technology captures the best of big data imaging and the artificial intelligence that operates on it.
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient's progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients. Scientists at The Neuro (Montreal Neurological Institute and Hospital) of McGill University and the Ludmer Centre for Neuroinformatics and Mental Health used an AI algorithm to analyze the blood and post-mortem brain samples of 1969 patients with Alzheimer's and Huntington's disease. Their goal was to find molecular patterns specific to these diseases. The algorithm was able to detect how these patients' genes expressed themselves in unique ways over decades.
In October 2019, pioneering neurotech startup Cognixion launched a turn-key, non-invasive artificial intelligence (AI) brain computer interface solution for healthcare that enables the speech impaired to noninvasively communicate their thoughts. It was a traumatic personal experience with his mother that triggered Andreas Forsland to startup the AI neurotech company a little over half a decade prior. The California sun was just starting to set in the horizon as Andreas Forsland rushed to the intensive care unit in Santa Barbara where his elderly mother was sedated, intubated and on life-support in 2012. The prognosis by the attending physician was grim--his mother was in septic shock due to advanced pneumonia, and was rapidly approaching kidney failure. "I hope you have your mother's affairs in order," advised the doctor to Forsland.
IBM Watson is known for its work in identifying cancer treatments and beating contestants on Jeopardy! But now the computing system has expertise in a new area of research: neuroscience. Watson discovered five genes linked to ALS, sometimes called Lou Gehrig's disease, IBM announced on Wednesday. The tech company worked with researchers at the Barrow Neurological Institute in Phoenix, Arizona. The discovery is Watson's first in any type of neuroscience, and suggests that Watson could make discoveries in research of other neurological diseases.